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Background: The aim of this study was to analyse the reasons for not starting or for early of radiotherapy at the
Radiation Oncology Department.
Methods: All radiotherapy treatments from March 2010 to February 2012 were included. Early withdrawals from
treatment those that never started recorded. Clinical, demographic and dosimetric variables were also noted.
Results: From a total of 3250 patients treated and reviewed, 121 (4%) did not start or complete the planned
treatment. Of those, 63 (52%) did not receive any radiotherapy fraction and 58 (48%) did not complete the course,
74% were male and 26% were female. The mean age was 67 ± 13 years. The most common primary tumour was
lung (28%), followed by rectum (16%). The aim of treatment was 62% radical and 38% palliative, 44% of patients
had metastases; the most common metastatic site was bone, followed by brain. In 38% of cases (46 patients)
radiotherapy was administered concomitantly with chemotherapy (10 cases (22%) were rectal cancers).
The most common reason for not beginning or for early withdrawal of treatment was clinical progression (58/121,
48%). Of those, 43% died (52/121), 35 of them because of the progression of the disease and 17 from other causes.
Incomplete treatment regimens were due to toxicity (12/121 (10%), of which 10 patients underwent concomitant
chemotherapy for rectal cancer).
Conclusions: The number of patients who did not complete their course of treatment is low, which shows good
judgement in indications and patient selection. The most common reason for incomplete treatments was clinical
progression. Rectal cancer treated with concomitant chemotherapy was the most frequent reason of the
interruption of radiotherapy for toxicity.
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unless otherwise stated.Quality assurance in health care has become more and
more important in recent years. Several papers have been
published on quality control in RT [1-6]. Our department
has great interest in quality assurance and has put an enor-
mous effort into its quality assurance programme. In 2000,
a quality assurance system project based on the so-called
International Organization for Standardizations (ISO)
9001 Quality Standards was started. One of the standards
applied in our quality assurance system was the number of
patients with incomplete treatments.
The aim of this study is to analyse the reasons for incom-
plete treatments at the Radiation Oncology Department.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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All treatments carried out at the Radiation Oncology
Department over a two-year period (from March 2010
until February 2012) were reviewed. Early withdrawals
and those patients that never started treatment were
recorded. Information regarding patients, demographic
characteristics, disease, treatment characteristics and
dosimetric variables were collected retrospectively from
the patients' records.
Our department receives patients for RT treatments
from different specialists from seven hospitals in the
province. We have a hospitalisation area where the pa-
tients' who need care are attended. Patients are admitted
for symptom control, for disease progression or for
toxicity treatment.
The planning process for RT includes the first consult-
ation including collecting the clinical history and exam-
ination of the patient. In this first consultation the
clinician explains the aim of treatment and its proce-
dures and informs patients and their families of the ben-
efits and any acute and/or late side effects they might
expect and patients sign the treatment consent form.
That same day, if the indicated treatment proceeds, the
clinical decides the position and immobilization of the
patient simulation and the acquisition of CT simulation.
Then we proceed to the prescription dose treatment and
delineation of tumour volumes and organs at risk, in
order to make the corresponding 3D dosimetry. Then
we review dosimetry, the treatment volumes as well as
histograms of the organs at risk. If treatment is accepted,
the patient starts treatment in the unit prior to perform-
ing verification.
The RT indication, radical vs. palliative, as well as the
need of a concomitant chemotherapy course is evaluated
by the attending clinician after assessment of general
conditions and co-morbidities of the patients. During
treatment, patients are scheduled for regular visits.
In our review, patients had been treated by standard
techniques at normo- or hypofractionation (1.8-8 Gy/
day) 5 days/week with a variety of equipment including
6–18 MV photons and/or 6–20 MeV electrons from the
linear accelerator. Our Department has 4 linear accelera-
tors, 1 ortho-voltage, and a high-dose brachytherapy
programme. All treatment planning was done in 3D.
In this study, we define incomplete treatment as a pa-
tient who has undergone at least one simulation/planning
procedure prior to starting an RT course; early withdrawal
means that a patient has received some irradiation treat-
ment fraction but failed to complete the scheduled course;
a non-starting patient is defined as one who did not
receive even a single fraction of radiation after the simula-
tion and planning. A compliant patient is therefore de-
fined as a patient who was able to complete the course of
radiation as intended.Statistical analysis
The results are shown as medians (± standard deviations).
Chi-square test was used to compare categorical variables.
Two-sided t-test was used to determine differences in
continuous variables. In the logistic regression model, we
included all predictor variables in the univariate analysis.
Values of p <0.05 were considered significant.
Results
A total of 3250 patients were treated during the analysed
period, RT was indicated (most frequent first) to treat
breast cancer (n = 748 patients, 23%), to improve symp-
toms (n = 715, 22%), to treat prostate cancer (n = 585,
18%), and to treat rectal cancer (n = 221, 7%).
Table 1 shows patient characteristics of all incomplete
treatments. It shows that 121/3250 patients (4%) were
incomplete treatments. Of those, 63/121 (52%) did not
receive any therapy fraction and the other 58/121 (48%)
did not complete the scheduled course, 74% of them were
male and 26% were female. The mean age was 67 ±
13 years. Mean distance from home to Department was
11 ± 16 Km. Fifty-eight percent of the patients travelled to
the Department by ambulance and 27% of them were
in-patients. The most common primary tumour location
was the lung (28%), followed by the rectum (16%). The
aim of treatment was radical in 62% and palliative in 38%
of cases. Metastases were evident in 44% of the patients.
The most common metastatic site was bone, followed by
brain. In 38% of cases (46/121 patients) RT was adminis-
tered concomitantly with chemotherapy (10/121 cases
(22%) were rectal cancers).
Mean time to the beginning of treatment was 7 ± 4 days.
Mean planned dose was 47 ± 18 Gy. Mean sessions sched-
uled 22 ± 12 Gy. Early withdrawal median dose 12 ± 17
Gy. Clinical progression was the most frequent reason for
incomplete courses (58/121, 48%). Patient death was the
cause of incomplete courses in 52 patients (43%), 35 of
them due to clinical progression and 17 from other causes.
Toxicity was responsible for incompleteness in 10% (12/
121) of patients, ten of them being rectal cancer patients
treated with concomitant chemotherapy.
Table 2 compares the characteristics between to non-
starting patients and early withdrawal patients.
We compared the non-compliant irradiation group with
the patients that finished their planned RT course. Men
were more frequently associated with non-compliant
irradiation courses (5%) than women (2%) (p < 0.005). A
slightly advanced age was significantly associated with
non-compliance (non-compliant courses, 67 ± 13 years,
completed courses, 65 ± 13 years). Palliative patients were
significantly more non-compliant than non-palliative
patients (6% vs. 3%; p < 0.005) but palliative patients were
slightly significantly younger (64 ± 13 years) than radical
patients (65 ± 13 years) (p = 0.049). There was a significant
Table 1 Patient characteristics of all incomplete
treatments
N %
Sex Male 89 74
Female 32 26




Metastasis Yes 41 34
No 80 66






Ambulance Yes 70 58
No 51 42
Inpatient Yes 33 27
No 88 73
Type of early withdrawal Incomplete course 58 48
Any fraction 63 52
Reason for withdrawal Death due to tumour progression 35 29
Clinical progression 23 19




Patient refusal 10 8
Dosimetric issues 5 4
Other 19 16
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compliance; the main locations were brain (10% of them),
lung (8% of them), rectum (7% of them) and head and neck
(6%) (p < 0.005). Despite that, a palliative course was asso-
ciated with bladder (59% of them), lung (58% of them), rec-
tum (17% of them), and breast (15% of them) (p < 0.005).
No significant differences in the planned dose were evi-
dent between patients who completed their irradiation
course (48 ± 21 Gy) and those non-compliant (47 ± 18 Gy).
Mean dose in the non-compliant course group, 12 ± 17 Gy.
No significant differences between non-starting patients
and early withdrawal patients were evident according to
the age, sex, location of the primary tumour, or planned
dose.
Table 3 summarizes the results of the logistic regres-
sion analysis for predictors of non-compliance among all
patients. Age, ambulance usage and primary tumour lo-
cation were significant. Sex and type of RT course werenot predictive of treatment discontinuation in the multi-
variate analysis.
Discussion
Radiation treatment is a complex procedure because it
requires highly specialized equipment and technology as
well as trained professionals.
Both the patient-related aspects (diagnosis, selection,
treatment indication, justification, referral, planning, ther-
apy, and follow-up) and the control and measurement
procedures that form the technical part of the treatment
process should be subject to regular planning, verification
and, mostly, constant improvement [7,8].
In this study, we focus on incompleteness of radiation
courses due to the well-established connection between
cancer treatment compliance and its outcomes [9-11]. A
correct evaluation of the parameters involved in non-
compliance has consequences, not only when selecting
patients for a radical/palliative treatment, but also when
planning RT resources and saving costs. The causes of
non-compliance to a prescribed treatment could be a
good quality indicator for an RT department because
they can show the accuracy of selection when prescrib-
ing irradiation.
Interruptions during the course of treatment include
planned unit maintenance and servicing, acute patient
toxicity and unexpected malfunction of linear accelera-
tors. Toxicity increases alongside concomitant chemo-
radiotherapy schedules. As far as we know, there are no
similar global studies published that have analysed early
withdrawal and non-starting irradiation factors in the
RT domain. Studies have focused on oncological non-
compliance treatments, analysing chemotherapy or
hormonal therapy or RT in a specific context. Some of
the most common topics are breast cancer [12-16] or
head and neck cancer [17,18] and insurance status
[13,14,17-20], which is related with the hospital type or
about elderly patients [16,18,21]. A global study
directed at analysing the duration of curative RT has
also been published [22], but it was aimed at evaluat-
ing ways to counteract short RT interruptions, such as
those caused by public holidays or machine mainten-
ance. Some factors associated with treatment interrup-
tions or early withdrawal, described in these published
studies, especially those related with health insurance
or financial issues, could not be included in our study
due to the big differences between the Spanish and
American Health Systems and the population sizes.
No irradiation compliance, as defined in the present
study, was very low (4%), the main causes being clinical
progression (48%) and death due to non-oncology rea-
sons. Male patients were more frequently non-compliant
in palliative treatments. Despite results showing a sig-
nificant slightly younger age for non-compliant patients,
Table 2 Characteristics of non-starting patients and early withdrawn patients
Non-starting Early withdrawal
N % N %
Sex Male 50 79 39 67 0.131
Female 13 21 19 33
Tumour location Lung 21 33 13 22 0.045
Rectum 4 6 15 26
Skin 5 8 9 16
Other 33 52 21 36
Metastasis Yes 16 25 25 43 0.04
No 47 75 33 57
Palliative Yes 19 30 27 47 0.063
No 44 70 31 53
Concomitant chemotherapy Yes 21 33 25 43 0.269
No 42 67 33 57
Ambulance Yes 30 48 40 69 0.022
No 32 52 18 31
Inpatient Yes 12 19 21 36 0.034
No 51 81 37 64
Reason for withdrawal Death due to tumour progression 17 27 18 31
Clinical progression 8 13 15 26
Non-oncology reasons 6 10 11 19 0.001
Toxicity 2 3 8 14
Patient refusal 10 16 2 3
Dosimetric issues 5 8 0 0
Other 15 24 4 7
Table 3 Multivariate logistic regression for predictors of
lack of treatment compliance among all patients
B Exp (B) 95% CI Sig.
RT course (radical) .354 1.424 .913 – 2.222 .119
Age -.021 .980 .964 - .996 .013
Ambulance use -.982 .374 .256 - .547 .000
Sex (female) .245 1.278 .783 – 2.085 .326
Primary location .000
Bladder 1.499 4.478 1.285 – 15.605 .019
Head & neck .345 1.412 .655 – 3.044 .378
Skin 1.837 6.276 2.475 – 15.913 .000
Breast 1.992 7.329 2.977 – 18.046 .000
Lung .252 1.287 .713 – 2.323 .403
Rectum .289 1.335 .662 – 2.693 .420
Lymphoma 1.190 3.287 .732 - 14.751 .120
Prostate 2.256 9.546 3.834 – 23.764 .000
Gynaecological 18.517 110098206.961 .000 - . .995
CNS -.165 .847 .329 – 2.185 .732
RT: radiotherapy; CNS: Central nervous system; 95% CI: 95% confidence interval.
Arenas et al. Radiation Oncology 2014, 9:260 Page 4 of 6
http://www.ro-journal.com/content/9/1/260the difference has no clinical relevance but is explained
by a the younger age of palliative patients. This is an
important finding because some studies have associated
advanced age with lower frequency of definitive or
adequate cancer treatment in some studies [23,24] even
though other studies suggest that older patients can
benefit similarly to younger patients [25,26] with high
rates of irradiation completion [16,18,21]. It is important
to keep one’s mind on carrying out an accurate compre-
hensive geriatric assessment because there is a possibility
of declining functional status [27] or even an early death
[28] due to cancer treatment in older patients.
Not surprisingly, patients with brain cancer or lung can-
cer were more frequently non-compliant. A previous re-
port from our group showed a 27% early withdrawal from
RTamong brain metastasis patients [29] stressing the need
for an accurate patient selection in order to avoid over-
treatment. Obviously the current study, which involves
curative and palliative patients, shows lower figures, with a
4% overall incidence of non-compliance. It should be
noted that concomitant chemotherapy for rectal cancer
was the most frequent reason for non-compliance due to
toxicity, nearly half of them by concomitant capecitabine,
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5-FU by oral capecitabine in concurrent treatment of
locally advanced rectal cancer with RT is generally well-
tolerated and effective [30-34]. Interestingly, we found that
the mean time for beginning treatment was 7 ± 4 days, so
the results presented here do not reflect delays due to the
health care system or waiting lists.
The main limitation of our study is the lack of add-
itional socio-economic or clinical data that might be
useful for designing preventive policies that avoid irradi-
ation discontinuation. Policies directed at predicting,
correcting and preventing treatment interruptions,
including integrated oncology care pathways, would re-
duce treatment variations and improve quality of patient
care and compliance with guidelines [35]. Central review
systems that have demonstrated an increase in CTV de-
lineation [36] could be expanded to clinical areas. In
spite of finding a slightly younger age associated with
non-compliance, there is a need for a comprehensive
geriatric assessment because it has shown to improve
elderly cancer patient care. A successful implementation
of such measures would result in improved patient out-
come as well as a more economical usage of resources.
Conclusions
This is the first study to our knowledge that reports the
incidence and the reasons for incomplete irradiation
courses. The overall number of non-compliant of patients
is low, showing good judgement in treatment and patient
selection.
The most frequent reason for incomplete treatment
was clinical progression. Toxicity during a rectal cancer
treatment, with concomitant chemotherapy, was the
most frequent reason for the interruption of curative
courses.
Summary
The reasons for not starting or early withdrawal of radio-
therapy are normally clinical and are not well established.
We analysed the patients who did not start radiotherapy
or who withdrew early at the Radiation Oncology Depart-
ment of University Hospital over a two year period. We
observed that the most common reason was clinical pro-
gression. Rectal cancer treated with concomitant chemo-
therapy was the most frequent reason for the radiotherapy
to be interrupted due to toxicity.
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